MaxCyte
MXCT----
Q2 FY2026 EarningsMXCT Q3 FY26 preliminary results significantly beat consensus, with total revenue reaching ~$9.1M vs. the $7.0M expected, a +29.6% surprise. Core business revenue grew 26% YoY to $8.1M, bolstered by accelerated instrument purchasing. Management raised FY26 revenue guidance to ~$34M from the previous $30M-$32M range, reflecting strong late-stage clinical program momentum and royalty visibility.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: MaxCyte(MXCT) the Revenue is 7.271 M (-14.53%), Beat estimate;the EBIT is -10.23 M (+28.08%), Beat estimate;the EPS is -0.08 (+33.33%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B14.53%
0.01B23.98%
+0.00B9.45%
EBITExceed expectations
-0.01B28.08%
-0.01B21.41%
+0.00B6.67%
EPSExceed expectations
-0.0833.33%
-0.0925.00%
+0.01008.33%
Upcoming earnings report - Q3 FY2026
Available dateNov 10, 2026
Estimate Revenue$7.469 M
Estimate EBIT-$9.668 M
Estimate EPS-$0.0775
Revenue
ActualEstimateUnit: USD
Quarterly
EBIT
ActualEstimateUnit: USD
Quarterly
Net income
ActualEstimateUnit: USD
Quarterly
EPS
ActualEstimateUnit: USD
Quarterly